Panagora Asset Management Inc Avadel Pharmaceuticals PLC Transaction History

Panagora Asset Management Inc

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2019 May 15, 2019	SELL	$1.44 - $3.29 $85,170 - $194,590	-59,146 Closed	0 $0
Q4 2018 Feb 14, 2019	BUY	$1.74 - $4.66 $80,240 - $214,895	46,115 Added 353.89%	59,146 $153,000
Q3 2018 Nov 13, 2018	SELL	$4.08 - $7.14 $151,433 - $265,008	-37,116 Reduced 74.01%	13,031 $57,000
Q2 2018 Aug 14, 2018	SELL	$5.89 - $7.78 $210,225 - $277,683	-35,692 Reduced 41.58%	50,147 $307,000
Q1 2018 May 15, 2018	BUY	$6.76 - $11.7 $457,895 - $792,511	67,736 Added 374.17%	85,839 $626,000
Q4 2017 Feb 14, 2018	SELL	$8.03 - $11.25 $3,766 - $5,276	-469 Reduced 2.53%	18,103 $148,000
Q3 2017 Nov 14, 2017	BUY	$8.35 - $10.5 $155,076 - $195,006	18,572	18,572 $195,000

1.07M

Ticker AVDL
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 60,581,300
Market Cap $650M
Description
Avadel Pharmaceuticals plc operates as a biopharmaceutical company in the United States. Its lead product candidate is FT218, a formulation of sodium oxybate, which is in a Phase 3 clinical trial for the treatment of excessive daytime sleepiness and cataplexy in adults with narcolepsy. The company was formerly known as Flamel Technologies SA and...

Get notified when there are updates to the investment portfolio of Panagora Asset Management Inc, based on Form 13F filings with the SEC.

Stay updated on Panagora Asset Management Inc with notifications on news.